{"entity":{"id":"nct06966453","kind":"trial","name":"A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer","aka":[],"tldr":"A phase 1/2 trial of Disitamab vedotin in advanced solid tumours, run by Pfizer, active and no longer recruiting.","summary":"A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer is a phase 1/2 interventional study registered as NCT06966453 by Pfizer, with 74 participants enrolled, started 2025-06-30 and due to reach its primary completion in 2027-10-25. Interventions recorded: Disitamab vedotin.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06966453","url":"https://clinicaltrials.gov/study/NCT06966453"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["disitamab-vedotin"],"companies":["pfizer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06966453","phase":"1/2","setting":"A PHASE 1B/2, OPEN-LABEL, MULTICOHORT STUDY OF DISITAMAB VEDOTIN IN ADULTS WITH HER2 EXPRESSING ADVANCED BREAST CANCER","sponsor":"Pfizer","enrolled":74,"outcomes":[]},"route":"/trials/nct06966453/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"disitamab-vedotin","kind":"drug","name":"Disitamab vedotin","route":"/drugs/disitamab-vedotin/"}],"company":[{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/"}]}}